Novartis' phase III PREVENT trial of Cosentyx in patients with nr-axSpA meets primary endpoint: Basel Wednesday, November 13, 2019, 09:00 Hrs [IST] Novartis, a leader in rheumatol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback